Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Endocrinology · Prediabetes

Medication Options: From Metformin to Newer Therapies

At a Glance

Lifestyle changes are the foundation of prediabetes care. Metformin may be considered for adults at higher risk, while semaglutide or tirzepatide may be discussed for obesity, although neither is approved for prediabetes; kidney function, side effects, and long-term plans require clinician review.

While lifestyle changes are the foundation of prediabetes care, they are not always enough to move blood sugar back into the normal range. For patients at higher risk, medications can provide a critical additional layer of protection against progression to type 2 diabetes [1][2].

Metformin: An Option for High-Risk Individuals

Metformin is the most well-studied medication for prediabetes. It works primarily by reducing the amount of sugar your liver produces and helping your muscles use insulin more effectively [3]. It is generally considered off-label for diabetes prevention in the U.S. and is not an automatic requirement.

Who is a Candidate?

The American Diabetes Association (ADA) suggests that metformin should be considered specifically for adults with prediabetes who have one or more “risk-enrichment” factors [1][4]:

  • Age: Generally adults aged 25–59.
  • Body Mass Index (BMI): 35 kg/m² or higher.
  • Blood Sugar Levels: A fasting glucose of at least 110 mg/dL or an HbA1c of at least 6.0%.
  • History: Women who previously had gestational diabetes (diabetes during pregnancy) [1][2].

Understanding the Risks and Side Effects

Metformin is generally safe, but it requires careful monitoring:

  • Gastrointestinal (GI) Issues: Nausea and diarrhea are common, affecting 20% to 30% of patients [5]. These symptoms are usually temporary and can often be managed by starting with a very low dose and gradually increasing it, or by using an extended-release (ER) version [5][6].
  • Vitamin B12 Deficiency: Long-term use can lower your B12 levels. After five years of use, about 19% of patients may develop low or borderline-low B12 [7]. Your doctor may recommend annual B12 testing to prevent complications like anemia or nerve damage [8].
  • Kidney Function: Metformin is cleared by the kidneys. Initiation is generally not recommended if your eGFR (a measure of kidney function) is 30–45, and it must be stopped if it falls below 30 to avoid a rare but serious condition called lactic acidosis [3][9].
  • “Sick Day” Rules: You should have an agreed plan with your prescriber to temporarily stop taking metformin if you become severely dehydrated, have a severe infection, or are vomiting, as these can suddenly strain your kidneys [10][11].

The Role of Incretin Therapies (GLP-1 and GIP)

A newer class of medications, including semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound), is emerging as a powerful tool for patients who have both prediabetes and obesity [12][13]. Note that these are approved for diabetes or chronic weight management, rather than formally for prediabetes itself.

  • How They Help: These medications mimic hormones called incretins that tell your brain you are full and tell your pancreas to release insulin when you eat [14].
  • Results: In clinical trials for weight management, semaglutide helped over 80% of participants with prediabetes return to normal blood sugar levels while losing an average of 15% of their body weight [15][12]. Tirzepatide has shown even greater weight loss potential, averaging over 20% in some studies [16].
  • The “Rebound” Risk: These medications are currently viewed as long-term treatments. Evidence shows that when the medication is stopped, most people regain a significant portion of the weight they lost—about two-thirds within a year in some cases [17][18]. This weight regain can cause blood sugar levels to rise again, potentially reversing the benefits [18].
  • Side Effects and Warnings: Like metformin, these primarily cause GI issues like nausea and vomiting, especially during the first few weeks [19][13]. Rare but serious risks include gallbladder problems and pancreatitis [19]. They carry a boxed warning regarding personal or family history of medullary thyroid carcinoma or MEN2, and they require special consideration during pregnancy.

Medication Decision Criteria

Your medical team will typically follow an individualized approach to adding medication:

  1. Lifestyle First: Start with the DPP goals (5–7% weight loss and 150 minutes of activity) [20].
  2. Consider Metformin: If blood sugar remains high or if you meet the high-risk criteria (BMI ≥35, prior gestational diabetes) [1].
  3. Consider Incretins: If obesity is a primary driver and lifestyle changes are not sufficient to achieve weight or health goals [15][21].

Always discuss your full medical history, including any kidney, digestive, or thyroid issues, with your doctor before starting these treatments.

Common questions in this guide

When might metformin be considered for prediabetes?
Metformin may be considered for adults with prediabetes who have higher-risk features such as being 25 to 59 years old, having a BMI of 35 or higher, fasting glucose of at least 110 mg/dL, HbA1c of at least 6.0%, or a history of gestational diabetes. It is not required for everyone, and a clinician should weigh it alongside lifestyle changes and your medical history.
What side effects and monitoring does metformin require?
Nausea and diarrhea are common at first and often improve with a gradual dose increase or an extended-release version. Long-term use can lower vitamin B12, so periodic B12 checks may be advised, and kidney function should be monitored because the dose may need adjustment when kidney function is reduced.
How does kidney function affect metformin use?
Metformin is cleared through the kidneys, so an eGFR blood test helps guide whether it is safe to start or continue. Starting metformin is generally not recommended when eGFR is 30 to 45, and it should be stopped if eGFR falls below 30 because of the rare risk of lactic acidosis.
When should I pause metformin during an illness?
Ask your prescriber in advance for a sick-day plan. Severe vomiting, diarrhea, dehydration, or a serious infection can suddenly strain the kidneys, and the plan may call for temporarily pausing metformin until you recover and receive medical guidance.
Are semaglutide and tirzepatide approved specifically for prediabetes?
Semaglutide and tirzepatide are approved for diabetes or chronic weight management, not specifically for prediabetes. A clinician may discuss them when obesity is a major health concern and lifestyle changes have not achieved weight or health goals, while considering your medical history and treatment risks.
What can happen if I stop a GLP-1 or GIP/GLP-1 medication?
Many people regain a significant amount of lost weight after stopping these medicines, with some studies finding that about two-thirds of the lost weight may return within a year. Weight regain can cause blood sugar to rise, so treatment should include a long-term plan with your clinician.
What warnings should I discuss before starting a GLP-1 or GIP/GLP-1 medicine?
These medicines commonly cause nausea or vomiting and can rarely cause gallbladder problems or pancreatitis. Tell your prescriber about a personal or family history of medullary thyroid cancer or MEN2, and discuss pregnancy plans before treatment.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my HbA1c, BMI, and age, am I a high-risk candidate for whom metformin might be considered under current ADA guidelines?
  2. 2.Should we check my Vitamin B12 levels now to establish a baseline, and how often will we monitor them while I am on metformin?
  3. 3.What is my current eGFR (kidney function), and at what level would we need to adjust or stop my medication?
  4. 4.If we consider a GLP-1 or GIP/GLP-1 medication for weight management, what is our long-term plan if I ever have to stop the medication?
  5. 5.Exactly what is our agreed 'sick day plan' for pausing metformin if I develop severe diarrhea or dehydration?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    The use of metformin for type 2 diabetes prevention: Observational multicenter study from Saudi Arabia.

    Alfayez OM, Alsallum AA, Aljabri AF, et al.

    Frontiers in public health 2022; (10()):989072 doi:10.3389/fpubh.2022.989072.

    PMID: 36159298
  2. 2

    Long-term Effects of Metformin on Diabetes Prevention: Identification of Subgroups That Benefited Most in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study.

    Diabetes care 2019; (42(4)):601-608 doi:10.2337/dc18-1970.

    PMID: 30877090
  3. 3

    Optimizing metformin therapy in practice: Tailoring therapy in specific patient groups to improve tolerability, efficacy and outcomes.

    Silverii GA

    Diabetes, obesity & metabolism 2024; (26 Suppl 3()):42-54 doi:10.1111/dom.15749.

    PMID: 38987983
  4. 4

    Diagnosis and Management of Prediabetes: A Review.

    Echouffo-Tcheugui JB, Perreault L, Ji L, Dagogo-Jack S

    JAMA 2023; (329(14)):1206-1216 doi:10.1001/jama.2023.4063.

    PMID: 37039787
  5. 5

    Organic cation transporter 1 variants and gastrointestinal side effects of metformin in patients with Type 2 diabetes.

    Dujic T, Causevic A, Bego T, et al.

    Diabetic medicine : a journal of the British Diabetic Association 2016; (33(4)):511-4 doi:10.1111/dme.13040.

    PMID: 26605869
  6. 6

    Effectiveness of an Incentives-Enhanced Stepped Care Intervention Program in Diabetes Prevention in a Multiethnic Asian Prediabetes Cohort: Results From the Pre-DICTED Randomized Controlled Trial.

    Bee YM, Awasthi N, Gandhi M, et al.

    Diabetes care 2025; (48(11)):1951-1959 doi:10.2337/dc25-1555.

    PMID: 40970814
  7. 7

    Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study.

    Aroda VR, Edelstein SL, Goldberg RB, et al.

    The Journal of clinical endocrinology and metabolism 2016; (101(4)):1754-61 doi:10.1210/jc.2015-3754.

    PMID: 26900641
  8. 8

    Association between metformin dose and vitamin B12 deficiency in patients with type 2 diabetes.

    Kim J, Ahn CW, Fang S, et al.

    Medicine 2019; (98(46)):e17918 doi:10.1097/MD.0000000000017918.

    PMID: 31725641
  9. 9

    Acute kidney injury, plasma lactate concentrations and lactic acidosis in metformin users: A GoDarts study.

    Connelly PJ, Lonergan M, Soto-Pedre E, et al.

    Diabetes, obesity & metabolism 2017; (19(11)):1579-1586 doi:10.1111/dom.12978.

    PMID: 28432751
  10. 10

    Metformin-associated lactic acidosis: A mini review of pathophysiology, diagnosis and management in critically ill patients.

    See KC

    World journal of diabetes 2024; (15(6)):1178-1186 doi:10.4239/wjd.v15.i6.1178.

    PMID: 38983827
  11. 11

    A Unique Case of Metformin-associated Severe Lactic Acidosis Without Preexisting Renal Disease: Perspectives on Prolonged Dialysis and Education for Prevention.

    Abad K, Kien C, Ganta K

    Cureus 2020; (12(4)):e7564 doi:10.7759/cureus.7564.

    PMID: 32382466
  12. 12

    Once-Weekly Semaglutide in Adults with Overweight or Obesity.

    Wilding JPH, Batterham RL, Calanna S, et al.

    The New England journal of medicine 2021; (384(11)):989-1002 doi:10.1056/NEJMoa2032183.

    PMID: 33567185
  13. 13

    Dose-Dependent Efficacy and Safety of Tirzepatide for Weight Loss in Non-diabetic Adults With Obesity: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

    Kasagga A, Assefa AK, Amin MN, et al.

    Cureus 2025; (17(6)):e85531 doi:10.7759/cureus.85531.

    PMID: 40630338
  14. 14

    Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease-Current Evidence.

    Muzurović EM, Volčanšek Š, Tomšić KZ, et al.

    Journal of cardiovascular pharmacology and therapeutics 2022; (27()):10742484221146371 doi:10.1177/10742484221146371.

    PMID: 36546652
  15. 15

    Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program.

    Perreault L, Davies M, Frias JP, et al.

    Diabetes care 2022; (45(10)):2396-2405 doi:10.2337/dc21-1785.

    PMID: 35724304
  16. 16

    Tirzepatide Versus Semaglutide for Weight Loss in Overweight and Obese Adults: A Systematic Review and Meta-Analysis of Direct Comparative Studies.

    Munawar N, Mahato A, Rawat A, et al.

    Cureus 2025; (17(6)):e86080 doi:10.7759/cureus.86080.

    PMID: 40666599
  17. 17

    Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.

    Rubino D, Abrahamsson N, Davies M, et al.

    JAMA 2021; (325(14)):1414-1425 doi:10.1001/jama.2021.3224.

    PMID: 33755728
  18. 18

    Causes and consequences of discontinuation of GLP1RAs or tirzepatide.

    Ceriello A, Prattichizzo F, Mastan Sheik Abdullah AR, et al.

    Nature reviews. Endocrinology 2026; (22(9)):530-542 doi:10.1038/s41574-026-01258-5.

    PMID: 42168641
  19. 19

    Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis.

    Tan HC, Dampil OA, Marquez MM

    Journal of the ASEAN Federation of Endocrine Societies 2022; (37(2)):65-72 doi:10.15605/jafes.037.02.14.

    PMID: 36578889
  20. 20

    The Stepwise Approach to Diabetes Prevention: Results From the D-CLIP Randomized Controlled Trial.

    Weber MB, Ranjani H, Staimez LR, et al.

    Diabetes care 2016; (39(10)):1760-7 doi:10.2337/dc16-1241.

    PMID: 27504014
  21. 21

    Tirzepatide and cardiometabolic parameters in obesity: Summary of current evidence.

    Sattar N, García-Pérez LE, Rodríguez A, et al.

    Diabetes, obesity & metabolism 2025; (27(10)):5386-5392 doi:10.1111/dom.16549.

    PMID: 40555920

This page explains medication options for prediabetes for informational purposes only and does not constitute medical advice. A clinician should review your kidney function, medical history, and treatment goals before you start or stop any medication.

Get notified when new evidence is published on prediabetes syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.